Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes

Next Previous
Trial Profile

Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Dulaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 7
  • Sponsors Novo Nordisk

Most Recent Events

  • 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
  • 26 Jun 2023 Results of an analysis assessing efficacy and safety of Tirzepatide, dulaglutide and Semaglutide (common comparator) using adjusted indirect comparisons using results data from two clinical trials: SURPASS-1 and SUSTAIN-7 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
  • 08 Aug 2022 Results published in the Diabetes Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top